Sunesis Pharmaceuticals Announces Presentations at ASH Annual Meeting

On November 5, 2015 Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) reported one oral presentation and two poster presentations at the 57th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting to be held December 5-8 in Orlando, Florida (Press release, Sunesis, NOV 5, 2015, View Source;p=RssLanding&cat=news&id=2107396 [SID:1234507997]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details for the oral presentation are as follows:

Date and Time: Monday, December 7, 2015 at 8:00 a.m. Eastern Time
Abstract Title: Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodyplastic Syndrome (MDS)
Session Number: 616
Session Name: Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Epigenetic Approaches
Publication Number: 461
Location: Orange County Convention Center, W109

The full abstract can be viewed here.

The details for the poster presentations are as follows:
Date and Time: Saturday, December 5, 2015 from 6:00 p.m. to 8:00 p.m. Eastern Time
Abstract Title: Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine in the Phase 3 VALOR Study
Session Number: 616
Session Name: Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Publication Number: 2560
Location: Orange County Convention Center, Hall A

The full abstract can be viewed here.

Date and Time: Saturday, December 5, 2015 from 5:30 p.m. to 7:30 p.m. Eastern Time
Abstract Title: A Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome
Session Number: 637
Session Name: Myelodysplastic Syndromes – Clinical Studies: Poster I
Publication Number: 1686
Location: Orange County Convention Center, Hall A

The full abstract can be viewed here.